# Verge Analytics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/verge-analytics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.vergegenomics.com
- Total disclosed funding: $136M
- Latest round: Series B (Feb 8, 2023)
- Investors on record: 23

## About

Founded in 2015 and based in California, US, Verge Analytics, Inc., dba Verge Genomics, engages in research on drug development for neurodegenerative disorders using artificial intelligence. The company was co-founded by its CEO, Alice Zhang, and others. In July 2021, Verge Analytics, Inc. raised USD 85 million in Series B funding from BlackRock, including Eli Lilly & Company, Merck Global Health Innovation Fund, Section 32, and Vulcan Capital, DFJ, LifeForce Capital, SUNU Ventures, and Tao Capital Partners, valuing the company at USD 214.93 million post-money.

The company’s pipeline includes VRG50635, which is a small-molecule inhibitor of PIKfyve, and it has already entered clinical trials for amyotrophic lateral sclerosis (ALS). This drug was discovered by its proprietary AI platform, converge®. Verge Genomics programs target therapeutic areas where multi-factorial components (genetics, environment, and time) intersect in complex ways to culminate in overt disease, and animal or cell models do not predict human efficacy. In addition, the company is also working on a variety of treatments, including treatments for Parkinson's disease, frontotemporal dementia, and other conditions that lack therapies. The firm’s partners include Alexion, Lilly, the University of Sheffield, and others.

## Funding rounds

- Series B, Feb 8, 2023 — Alumni Ventures Group
- Series B, Jul 2, 2021, $85M — Merck Global Health Innovation Fund, Vulcan, BlackRock, Eli Lilly & Company, Tao Capital Partners, SUNU Ventures, Section 32, LifeForce Capital, Threshold Ventures
- Series A, Jul 22, 2020, $11M — Tao Capital Partners, SUNU Ventures, LifeForce Capital, Threshold Ventures
- Series A, Jul 16, 2018, $36M — Draper Fisher Jurvetson, Great Oaks Venture Capital, Awaken Capital, SUNU Ventures, LifeForce Capital, Agent Capital, Basis Set, Threshold Ventures, Wuxi AppTec Group
- Seed, Oct 29, 2015, $4M — Two Sigma Investments, IA Ventures, Great Oaks Venture Capital, Slow, Karlin Ventures, Draper, Awaken Capital, Refactor Capital
- Seed, Jul 22, 2015, $0.1M — Y Combinator

## Investors

- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed
- Two Sigma Investments (https://capitalatlas.ai/funds/two-sigma-investments) — Seed
- IA Ventures (https://capitalatlas.ai/funds/ia-ventures) — Seed
- Great Oaks Venture Capital (https://capitalatlas.ai/funds/great-oaks-venture-capital) — Seed, Series A
- Slow (https://capitalatlas.ai/funds/slow) — Seed
- Karlin Ventures (https://capitalatlas.ai/funds/karlin-ventures) — Seed
- Draper (https://capitalatlas.ai/funds/draper) — Seed
- Awaken Capital (https://capitalatlas.ai/funds/awaken-capital) — Seed, Series A
- Refactor Capital (https://capitalatlas.ai/funds/refactor-capital) — Seed
- Draper Fisher Jurvetson (https://capitalatlas.ai/funds/draper-fisher-jurvetson) — Series A
- SUNU Ventures (https://capitalatlas.ai/funds/sunu-ventures) — Series A, Series B
- LifeForce Capital (https://capitalatlas.ai/funds/lifeforce-capital) — Series A, Series B
- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Series A
- Basis Set (https://capitalatlas.ai/funds/basis-set) — Series A
- Threshold Ventures (https://capitalatlas.ai/funds/threshold-ventures) — Series A, Series B
- Wuxi AppTec Group — Series A
- Tao Capital Partners (https://capitalatlas.ai/funds/tao-capital-partners) — Series A, Series B
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series B
- Vulcan (https://capitalatlas.ai/funds/vulcan) — Series B
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series B
- Eli Lilly & Company — Series B
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series B
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series B